What is your approach for adjuvant therapy when a patient has discordant Oncotype RS (e.g. <20) and MammaPrint (e.g. high risk Luminal B) in node negative HR+Her2- breast cancer?
Answer from: Medical Oncologist at Academic Institution
In terms of the Mammprint, the question here is whether the patient is at low clinical risk or high clinical risk. A stage 1 patient is likely to be considered low clinical risk. In these patients, the MINDACT trial showed that Mammaprint was not able to accurately predict the benefit of chemotherap...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
I have started using Mammaprint in low clinical risk patients to identify patients that might be able to safely stop endocrine therapy early (the ultra-low risk patients). However, I then wonder if it makes sense to also check an Oncotype in case Mammaprint comes back as high risk to find out if the...